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We investigated the association between urinary tract infections (UTIs) and transitional cell carcinoma of the bladder in a population-
based case–control study in Los Angeles covering 1586 cases and age-, gender-, and race-matched neighbourhood controls.
A history of bladder infection was associated with a reduced risk of bladder cancer among women (odds ratio (OR), 0.66; 95%
confidence interval (CI), 0.46–0.96). No effect was found in men, perhaps due to power limitations. A greater reduction in bladder
cancer risk was observed among women with multiple infections (OR, 0.37; 95% CI, 0.18–0.78). Exclusion of subjects with a history
of diabetes, kidney or bladder stones did not change the inverse association. A history of kidney infections was not associated with
bladder cancer risk, but there was a weak association between a history of other UTIs and slightly increased risk among men. Our
results suggest that a history of bladder infection is associated with a reduced risk of bladder cancer among women. Cytotoxicity from
antibiotics commonly used to treat bladder infections is proposed as one possible explanation.
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Urinary tract infections (UTIs) are the most common kidney and
urologic diseases in the US, especially among women. About 50%
of women have at least one symptomatic infection during their
lifetime, and many have recurrent episodes (Stamm, 2002).
However, UTIs in men are uncommon until after age 50, and are
usually indicative of an underlying urologic abnormality (Stamm
and Hooton, 1993). In the US, the majority of uncomplicated UTIs
are caused by Escherichia coli (80%) or Staphylococcus saprophyticus
(10–15%) (Stamm, 2002). An experimental study in rats has
shown associations between chronic infections with Escherichia
coli and early bladder neoplasia (Davis et al, 1991), and it has been
suggested that the high rates of bladder cancer in some parts of
Africa and the Middle East may be due to the high prevalence of
chronic infection with Schistosoma haematobium (IARC, 1994). A
review of published epidemiological studies regarding the
association between bladder infections and transitional cell
carcinoma (TCC), the predominant type in developed countries,
shows inconsistent results (Howe et al, 1980; Kantor et al, 1984;
Claude et al, 1986; Piper et al, 1986; Kjaer et al, 1989; Gonzalez
et al, 1991; La Vecchia et al, 1991; Sturgeon et al, 1994; Jhamb et al,
2007) and reveals a need for future studies to determine whether
UTIs increase the risk of bladder cancer.
We collected detailed information on UTIs in a large popula-
tion-based case–control study of bladder cancer in Los Angeles
County, where we have identified risk factors including cigarette
smoking (Castelao et al, 2001) and use of permanent hair dyes
among women (Gago-Dominguez et al, 2001, 2003), and protective
factors including use of non-steroidal anti-inflammatory drugs
(NSAIDs) (Castelao et al, 2000) and consumption of carotenoids
and vitamin C (Castelao et al, 2004).
MATERIALS AND METHODS
Cases were identified through the Los Angeles County Cancer
Surveillance Program – the largest of the National Cancer
Institute’s Surveillance, Epidemiology and End Results (SEER)
cancer registries (Bernstein and Ross, 1991). Eligibility criteria
included histologically confirmed bladder cancers diagnosed
between January 1, 1987 and April 30, 1996 among non-Asians
between the ages of 25 and 64 years. In total, 2384 cases were
identified. Of these, 210 (9%) died before we could contact them or
were too ill to be interviewed. Permission to contact 99 (4%)
patients was denied by their physicians, and 404 (17%) patients
declined to participate in the study. We interviewed 1671 (70%) of
the cases.
For each enrolled case, a standard procedure was followed to
recruit a control subject from the neighbourhood of the residence
of the case at the time of cancer diagnosis, with the control
matched to the case by age (within 5 years), sex, and race
(non-Hispanic white, Hispanic white, or African American/others).
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of each housing unit; ‘not at home’ units were systematically
revisited to complete the census. The first resident along this
defined route who satisfied all eligibility criteria for controls was
asked to participate in this study (i.e. first eligible control). If that
individual refused, the next eligible control (i.e. second eligible
control) in the sequence was asked and so on until we located an
eligible control who agreed to be interviewed. When we failed to
find any resident who met our matching criteria after canvassing
150 housing units, we excluded race from the matching criteria. If
a matched control subject based on this relaxed criterion could not
be found within a maximum of 300 housing units, the case was
dropped from the study. For the 1671 interviewed patients, a
matched control could not be found for 5% (85) of the interviewed
cases. Among the 1,586 eligible control subjects, 1090 (69%)
control subjects were first eligible controls, 325 (20%) were second
eligible controls and 111 (7%) were third eligible controls, and the
remaining 60 (4%) control subjects were fourth or higher eligible
controls. Twenty-one control subjects were not matched to the
index case by race. Therefore, a total of 1586 pairs of cases and
controls were included in the analyses. All study subjects signed
informed consent forms. The study was approved by the
Institutional Review Board at the University of Southern
California, Keck School of Medicine.
All study cases and controls were interviewed at home by
trained interviewers using a structured questionnaire. The
structured questionnaire requested information up to 2 years
before diagnosis of cancer for the cases, and up to 2 years before
diagnosis of cancer of the index case for the matched controls (i.e.
reference year). Each subject was asked to report information on
demographic characteristics, lifetime use of tobacco products and
alcohol, usual adult dietary habits, lifetime occupational history,
prior medical conditions, and prior use of medications. The
questionnaire included questions on history of physician-
diagnosed hypertension, diabetes, angina, heart attack, stroke,
analgesic nephropathy, renal papillary necrosis, kidney/renal
stones, bladder stones, polycystic kidney disease, hereditary
kidney disease, and injury to kidney. After January 1992, a history
of tuberculosis, thyroid disease, polycythemia vera, and gout was
also asked. For each medical condition, we asked the year of first
diagnosis by a doctor. In addition, we asked the participants if they
were told by a doctor that they had kidney infections, bladder
infections, or other type of UTIs. If so, the year of first and last
diagnosis and total number of diagnoses were also requested.
Statistical analysis
The associations of bladder cancer with medical histories were
measured by odds ratios (ORs) and their corresponding 95%
confidence intervals (CIs) and P-values. Conditional logistic
regression models were used to examine the relationship between
any medical history and bladder cancer risk with adjustment for
the following risk factors for bladder cancer: number of cigarettes
smoked per day, number of years of smoking, smoking status in
the reference year (smoker or nonsmoker) (Castelao et al, 2001),
level of education (high school or less, some college, college or
above), total number of NSAID pills used over the lifetime (non/
irregular user, o1441 pills, X1441 pills used over lifetime)
(Castelao et al, 2000), intake of carotenoids (quintiles) (Castelao
et al, 2004), and duration of employment as a hairdresser/barber
(years) (Castelao et al, 2001). There were no material changes in
the results with further adjustment for hair dye use, and thus this
variable was not retained. Unconditional logistic regression was
used in the analyses stratified by smoking status (lifetime
nonsmokers vs ever smokers). In addition to all the covariates
mentioned above, strata defined by age and sex (age groups of
o46, 46–50, 51–55, 56–60, and 460 years for each sex), and
racial/ethnic groups (non-Hispanic white, Hispanic white, or
African American/others) were included in the regression model
to account for the matched sampling. All results were similar when
we limited our analyses to non-Hispanic whites only, or when we
excluded from our analyses the case–control pairs that were not
matched on race. Owing to this, and in order to maximize our
study power, all study subjects were included in our analyses.
Statistical analyses were performed using the SAS version 9.1
(SAS Institute Inc., NC, USA). ORs with two-sided P-values o0.05
were considered statistically significant. All P-values, estimated
from likelihood ratio test, were two-sided.
RESULTS
A history of one or more UTIs was reported by 26% of cases and
28% of controls (Table 1), occurring more frequently in women
(47% of cases and 57% of controls) than in men (20% of cases and
20% of controls). In women, the most frequent UTIs were bladder
infections; in men, however, UTIs occurred more frequently in
urinary tract organs other than the kidney and bladder,
presumably in the urethra and ureter. Thus, among the 200
control women reporting a history of UTI, 169 (85%) reported a
Table 1 Urinary tract infections and risk of bladder cancer by sex
All Men Women
History of Cases/controls OR
a (95% CI) Cases/controls OR
a (95% CI) Cases/Controls OR
a (95% CI)
Any urinary tract infection
No 1172/1144 1.00 988/995 1.00 184/149 1.00
Yes 414/442 1.00 (0.83–1.20) 249/242 1.15 (0.92–1.44) 165/200 0.74 (0.53–1.03)
Bladder infection
b
No 1365/1317 1.00 1148/1137 1.00 217/180 1.00
Yes 221/269 0.80 (0.63–1.02) 89/100 0.96 (0.69–1.35) 132/169 0.66 (0.46–0.96)
Kidney infection
b
No 1480/1491 1.00 1179/1185 1.00 301/306 1.00
Yes 106/95 1.10 (0.80–1.52) 58/52 1.01 (0.65–1.55) 48/43 1.26 (0.76–2. 07)
Other urinary infection
b
No 1443/1453 1.00 1108/1122 1.00 335/331 1.00
Yes 143/133 1.28 (0.96–1.70) 129/115 1.35 (0.99–1.83) 14/18 0.76 (0.33–1.75)
aConditional logistic regression, adjusted for level of education, use of NSAIDs, intake of carotenoids, number of years as a hairdresser/barber, cigarette-smoking status, duration
of smoking, and intensity of smoking.
bAdditional adjustment for infections at the other two sites did not materially change the associations.
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and only 18 reported (9%) other UTIs. The corresponding figures
among the 242 control men reporting a history of UTI were 100
(41%), 52 (21%), and 115 (48%), respectively.
A history of any UTI was not associated with bladder cancer
among all subjects, men and women combined (OR, 1.00; 95% CI,
0.83–1.20; Table 1). Women reporting a history of UTI had a 26%
reduction in bladder cancer risk (OR, 0.74; 95% CI, 0.53–1.03)
than women reporting no history of any UTI; however, this
reduction did not reach statistical significance. A history of kidney
infection or other UTIs was not significantly associated with
bladder cancer; however, the risk was slightly elevated at border-
line significance level among men reporting a history of other UTIs
(OR, 1.35; 95% CI, 0.99–1.83), especially among those reporting
infection occurring within 5 years of cancer diagnosis (within 5
years of cancer diagnosis: OR, 3.01; 95% CI, 1.26–7.23; X5 years
before cancer diagnosis: OR, 1.17; 95% CI, 0.83–1.64).
Bladder infections were much more frequent among women
than among men in our study (48 vs 8%, respectively). Overall, a
history of bladder infection was associated with a slightly reduced
risk of bladder cancer (OR, 0.80; 95% CI, 0.63–1.02; Table 1),
although the association was not statistically significant. This
inverse association was, however, seen only in women (OR, 0.66;
95% CI, 0.46–0.96). Exclusion of women with a bladder infection
within 5 years of cancer diagnosis strengthened the inverse
association (OR, 0.52; 95% CI, 0.34–0.81; Table 2), suggesting that
the observed inverse bladder infection–bladder cancer association
was unlikely to be caused by bladder infections resulting from the
bladder cancer. Thus, all subsequent analyses were restricted to
women who did not have a history of recent bladder infections. We
also assessed the association between number of episodes of
bladder infections and bladder cancer risk. The largest reduction
in risk was observed in women with more than three episodes of
infections (OR, 0.37; 95% CI, 0.18–0.78; Table 2). We also explored
the potential modifying effect of age at first and last infection in
our observed inverse association, although the data were too
sparse to make any strong conclusions. Among women who did
not report a history of recent bladder infections, the reported
median ages at first and last infection were 29 and 37 years,
respectively. The infection-associated reduction in risk seemed to
be similar between women who had their first episode of
bladder infection at a younger age (o29) and those who had
their first episode of bladder infection at an older age (X29)
(Pheterogeneity¼0.76). Similarly, no significant differences in risk
were observed by age at last infection (Pheterogeneity¼0.81).
The inverse association between bladder infections and bladder
cancer was observed in all categories of smoking (Table 3),
although the association was particularly strong among former
smokers (PX1 vs 0¼0.002). The OR associated with a history of
multiple bladder infections (43) was 0.43 (95% CI, 0.11–1.68)
Table 2 Bladder infections and risk of bladder cancer in women
Cases/controls OR
a (95% CI)
History of bladder infection
No 217/180 1.00 (reference)
Yes 132/169 0.66 (0.46–0.96)
Pyes vs no
b 0.027
Duration between last infection and cancer diagnosis (years)
Unknown 23/20 0.82 (0.38–1.76)
o5 39/39 1.03 (0.55–1.93)
X5 70/110 0.52 (0.34–0.81)
Pyes (X5) vs no
b 0.003
Number of episodes of infection
c
1 30/40 0.65 (0.34–1.24)
2–3 23/36 0.54 (0.28–1.07)
43 17/34 0.37 (0.18–0.78)
Ptrend
d 0.29
Age at first infection (years)
c,e
o29 (median) 35/51 0.52 (0.30–0.92)
X29 34/58 0.51 (0.29–0.90)
Pheterogeneity
d 0.76
Age at last infection (years)
c
o37 (median) 36/54 0.52 (0.29–0.92)
X37 34/56 0.53 (0.30–0.93)
Pheterogeneity
d 0.81
aConditional logistic regression, adjusted for level of education, use of NSAIDs, intake
of carotenoids, number of years as a hairdresser/barber, cigarette-smoking status,
duration of smoking, and intensity of smoking.
bLikelihood ratio test for history of
bladder infection (yes vs no).
cWomen with a bladder infection occurring within 5
years of cancer diagnosis were excluded.
dSubjects without a history of bladder
infection were removed for purposes of calculating P-values based on the likelihood
ratio tests for trend or heterogeneity.
eData on age at first infection were missing for
one case and one control.
Table 3 Bladder infections and risk of bladder cancer in women by
cigarette smoking
No. of episodes of
bladder infection
a Cases/controls OR (95% CI)
Non-smokers
b
0 43/88 1.00
X1 14/44 0.63 (0.30–1.33)
PX1 vs 0
c 0.20
1 7/17 0.79 (0.29–2.16)
2–3 4/14 0.62 (0.18–2.13)
43 3/13 0.43 (0.11–1.68)
Ptrend
d 0.42
Smokers
e
0 174/92 1.00
X1 56/66 0.52 (0.33–0.83)
PX1 vs 0
c 0.005
1 23/23 0.61 (0.31–1.20)
2–3 19/22 0.50 (0.25–1.01)
43 14/21 0.45 (0.21–0.97)
Ptrend
d 0.57
Former smokers
f
0 54/47 1.00
X1 21/44 0.35 (0.17–0.73)
PX1 vs 0
c 0.002
1 10/14 0.58 (0.21–1.60)
2–3 5/14 0.31 (0.09–1.06)
43 6/16 0.21 (0.07–0.68)
Ptrend
d 0.19
Current smokers
f
0 119/45 1.00
X1 35/22 0.61 (0.31–1.21)
PX1 vs 0
c 0.18
1 13/9 0.46 (0.17–1.29)
2–3 14/8 0.73 (0.27–1.96)
43 8/5 0.69 (0.20–2.39)
Ptrend
d 0.64
aWomen with a bladder infection occurring within 5 years of cancer diagnosis were
excluded from the analyses.
bUnconditional logistic regression, adjusted for age, race,
level of education, use of NSAIDs, and intake of carotenoids.
cLikelihood ratio test for
history of bladder infection (X1 vs 0).
dSubjects without a history of bladder infection
were removed for purposes of calculating P-values based on the likelihood ratio tests
for trend.
eUnconditional logistic regression, adjusted for age, race, level of education,
use of NSAIDs, intake of carotenoids, cigarette-smoking status, duration of smoking,
and intensity of smoking. Due to sample size limitation, number of years as a
hairdresser/barber was excluded from regression model.
fOne case with unknown
smoking status at reference year was excluded from the analyses.
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0.69 (0.20–2.39) among current smokers.
In our study population, control subjects with a history of
bladder infection were more likely to use NSAIDs (42.7%) than
those without such a history (33.3%, P¼0.004). Therefore we
further analysed data stratified by the use of NSAIDs. The inverse
association between bladder infection and bladder cancer among
women was present in both users (OR, 0.54; 95% CI, 0.29–1.03)
and non-users of NSAIDs (OR, 0.52; 95% CI, 0.31–0.87), with a
P-value of 0.87 for the interaction between use of NSAIDs and
bladder infection on cancer risk (data not shown).
To investigate whether the bladder infection-bladder cancer
association varied across strata defined by other known risk/
protective factors in this study, including age, level of education
(Jiang et al, 2007), alcohol consumption (Jiang et al, 2007), water
intake (Jiang et al, 2008), and intake of carotenoids (Castelao et al,
2004), stratified models were fit according to the levels of those
variables. An inverse association between bladder infection and
bladder cancer was observed in virtually all subgroups (data not
shown).
Regarding grade and stage of disease, a history of bladder infection
was significantly associated with a reduced risk of only invasive (T1–
T4) bladder cancers (PX1 vs 0¼0.005; Table 4), but not non-invasive
(Ta) bladder cancers (PX1 vs 0¼0.11). In addition, the protective
effect differed by grade, with the effect being more pronounced for
high-grade (grade 3–4) cancers (PX1 vs 0¼0.0004).
A history of diabetes was associated with an increased risk of
bladder cancer (OR, 1.70; 95% CI, 1.18–2.45), whereas a history of
kidney stones was associated with a slight increase in bladder
cancer risk (OR, 1.24; 95% CI, 0.94–1.64). A history of bladder
stones, which was reported only by very few subjects (10 cases and
11 controls), was not associated with bladder cancer risk (OR, 0.79;
95% CI, 0.30–2.10). The inverse association with bladder
infections was materially unchanged after excluding subjects with
a history of diabetes, kidney, and/or bladder stones.
DISCUSSION
UTIs are very common among women (Stamm, 2002), but
uncommon among men until after the age of 50 years (Stamm
and Hooton, 1993). Bladder infection is the most common UTI
among women in the US (Sheffield and Cunningham, 2005). Our
study found a significant association between bladder infections
and reduced risk of bladder cancer among women, with the highest
protection found among women who experienced multiple
infections. This inverse association was confined to invasive
high-grade bladder cancers.
A number of case–control studies have examined the possible
association of UTIs with bladder cancer in developed countries
(Howe et al, 1980; Kantor et al, 1984; Claude et al, 1986; Piper et al,
1986; Kjaer et al, 1989; Gonzalez et al, 1991; La Vecchia et al, 1991;
Sturgeon et al, 1994; Jhamb et al, 2007). The overall evidence
supports an increased risk from UTIs. However, in general, a much
higher risk was observed for infections occurring approximately
within 5 years of cancer diagnosis, and the risk was substantially
reduced or disappeared when infections occurred many years
before cancer diagnosis (Howe et al, 1980; Gonzalez et al, 1991; La
Vecchia et al, 1991; Jhamb et al, 2007). As the dates of UTIs were
not obtained in all these studies, it is also possible that the
occurrence of UTIs may be a consequence of early bladder cancer
before its diagnosis, rather than a cause of the disease.
Alternatively, UTIs may have a later-stage effect in bladder
carcinogenesis by promoting initiated tumors (La Vecchia et al,
1991). In addition, studies that found increased risks from UTIs
(Claude et al, 1986; Kantor et al, 1988; Gonzalez et al, 1991) did not
discriminate between the different types of UTI. This is an
important consideration, as different types of UTI may have
different impacts on bladder cancer risk. A history of cystitis has
been reported to be associated with an increased bladder cancer
risk, but a history of kidney infection was associated with a
significantly decreased risk (Jhamb et al, 2007). In our study, a
decreased risk of bladder cancer for bladder infections was found
among women, but an increased risk for infections occurring in
urinary tract organs other than kidney and bladder, presumably
urethra, was found in men. The majority of urethritis in men are
secondary to sexually transmitted diseases such as chlamydia and
gonorrhoea (Wong and Stamm, 1983), which has been found to be
associated with a significantly increased risk in three studies
(Mommsen and Sell, 1983; La Vecchia et al, 1991; Michaud et al,
2007). If a history of UTI indeed increased the risk, one would
expect a higher incidence of bladder cancer among women than
among men, as well as a higher incidence of squamous cell
carcinoma of the bladder vs TCC (Burin et al, 1995). However,
bladder cancer is 3–4 times more common in men than in women,
and approximately 90% of bladder cancer in the US are TCCs (with
only 7% being of squamous cell carcinoma type) (Yu and Ross,
Table 4 Bladder infections and risk of bladder cancer in women by
histology
No. of episodes of
bladder infection
a Cases/controls OR
b (95% CI)
Stage
c
Ta
0 117/102 1.00
X1 43/60 0.70 (0.39–1.25)
PX1 vs 0
d 0.11
1 20/26 0.81 (0.37–1.78)
2–3 13/15 0.74 (0.29–1.92)
43 10/19 0.53 (0.21–1.31)
Ptrend
e 0.71
T1–T4
0 93/70 1.00
X1 22/42 0.24 (0.09–0.62)
PX1 vs 0
d 0.005
1 9/11 0.41 (0.10–1.62)
2–3 8/18 0.26 (0.06–1.04)
43 5/13 0.05 (0.004–0.52)
Ptrend
e 0.22
Grade
c
Grade 1–2
0 148/129 1.00
X1 55/76 0.72 (0.44–1.20)
PX1 vs 0
d 0.11
1 25/30 0.93 (0.46–1.89)
2–3 17/23 0.64 (0.29–1.44)
43 13/23 0.56 (0.24–1.32)
Ptrend
e 0.46
Grade 3–4
0 67/48 1.00
X1 12/31 0.07 (0.02–0.34)
PX1 vs 0
d 0.0004
1 4/8 0.06 (0.004–0.98)
2–3 5/12 0.13 (0.02–1.05)
43 3/11 0.03 (0.002–0.49)
Ptrend
e 0.47
aWomen with a bladder infection occurring within 5 years of cancer diagnosis were
excluded from the analyses.
bConditional logistic regression, adjusted for level of
education, use of NSAIDs, intake of carotenoids, number of years as a hairdresser/
barber, cigarette-smoking status, duration of smoking, and intensity of smoking.
cSix
cases with unknown stage, eleven Tis cases, seven cases with unknown grade, and
their matched controls were excluded from the relevant analyses.
dLikelihood ratio
test for history of bladder infection (X1 vs 0).
eSubjects without a history of bladder
infection were removed for purposes of calculating P-values based on the likelihood
ratio tests for trend.
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infections induce squamous metaplasia of the bladder, a process
that may subsequently lead to squamous cell carcinoma of the
bladder, but not to TCC (Burin et al, 1995), which is also supported
by the strong associations between bladder infections and
squamous cell carcinomas of the bladder, and not with TCC
(IARC, 1994; Burin et al, 1995; Michaud, 2007).
Our study found a significant association between bladder
infections, especially multiple infections, and reduced risk of
bladder cancer. There are several possible reasons to explain these
findings: (1) the anti-cancer effect of antibiotics used to treat
bladder infections; (2) the higher intake of NSAIDs among subjects
with a history of bladder infection; and (3) the immune response
triggered by bladder infection.
In experimental studies, antibiotics used to treat bladder
infections have been found to inhibit bladder cancer growth (Seay
et al, 1996; Ebisuno et al, 1997; Aranha et al, 2000, 2002; Kamat
and Lamm, 2004). The traditional treatment of uncomplicated
UTIs has been a short course of antibiotics such as amoxicillin,
trimethoprim (TMP) alone or with sulfamethoxazole (TMP-SMX),
nitrofurantoin, cephalosporins, and fosfomycin (Stamm, 2002).
Antibiotic agents preferred for UTIs are agents that are primarily
excreted through the urinary tract and achieve prolonged and high
concentrations in the urine (Stamm, 2002). About 70–90% of TMP
and 30% of SMX are excreted unchanged in the urine (Masters
et al, 2003). Besides their bactericidal effect, the commonly used
antibiotics TMP-SMX, cefazolin (cephalosporin), and nitrofuran-
toin significantly inhibited cell proliferation in human TCC cell
lines (Seay et al, 1996), producing a proliferation inhibition rate as
high as 95%. Inhibition occurred in a dose-dependent manner at
concentrations attainable in the urine after oral administration
(Kamat and Lamm, 2004). Similar dose–response anti-cancer
effects were shown for ciprofloxacin or other fluoroquinolones
(Seay et al, 1996; Ebisuno et al, 1997; Kamat and Lamm, 2004). The
mechanism for the antibiotics’ cytotoxicity against bladder cancer
cells remains unclear. Ciprofloxacin has been shown to cause cell-
cycle arrest, disruption of calcium homeostasis, mitochondrial
swelling, and redistribution of Bax (a pro-apoptotic protein) to the
mitochondrial membrane, eventually leading to apoptosis in
human TCC lines (Aranha et al, 2000, 2002).
As subjects with a history of bladder infection were more likely
to use NSAIDs regularly than subjects without such a history, and
intake of NSAIDs was earlier found to be negatively associated
with bladder cancer in this population (Castelao et al, 2000), the
inverse association risk was plausibly the result of excessive use of
NSAIDs among subjects with a history of bladder infection.
However, the protective effect of bladder infection was observed
among both regular users and non- or irregular users of NSAIDs;
therefore, the use of NSAIDs was unlikely to explain our observed
protective effect.
Another mechanism that may explain our finding is the anti-
cancer effect of the immune response triggered by bladder
infections. BCG immunotherapy for bladder cancer has been
widely accepted for its effect in decreasing recurrence rates and in
increasing median time to recurrence (Alexandroff et al, 1999).
BCG infection induces release of chemokines/cytokines, attracts
and activates neutrophils, macrophages and T-cells, resulting in
improved recognition and killing of tumor cells (Alexandroff et al,
1999). Bladder infection, which is mostly caused by E. coli in
humans, may trigger an immune response similar to BCG
treatment, killing hyperplastic cells before they transform into
cancerous cells (Zasloff, 2007).
The infection–cancer association was modified by frequency of
bladder infections, with the highest reduction in risk confined to
women with X2 bladder infections. An estimated 20–30% of
women with a first UTI will have recurrent episodes, and 5% will
have chronic recurrent infections (Foxman et al, 2000). For women
who have recurrent infections, a low-dose antimicrobial prophy-
laxis taken daily or thrice weekly for 3–6 months is recommended
to prevent recurrent infections (Stamm and Hooton, 1993; Fihn,
2003). Dosage seems to play a role in the anticancer effect of
antibiotics, as the cancer-killing effect has been shown to be
irreversible only at high doses (i.e. 250mgml
–1 ciprofloxacin)
(Zehavi-Willner and Shalit, 1992).
Compared with early studies, we were able to obtain the age at
first and last infection and were therefore able to identify that the
infection was not likely a result of bladder cancer and, that
detection bias could not explain our results. We were also able to
exclude subjects reporting a history of diabetes, kidney stones, and
bladder stones and therefore eliminate the possibility that the
effect of bladder infections could be so explained. Some of our
subgroup analyses, especially those conducted among women with
specific smoking status or histology, were based on very small
numbers; so interpretation must be cautious. We also had power
limitations in such groups, as infection before age 20 or after age
49, which would have been potentially interesting with greater
numbers. Thus, in order to ensure proper study power, median
ages were used as cut-off points. Also, information on antibiotic
therapy associated with UTIs and other diseases was not requested.
Recall bias (i.e. the possibility that cancer patients were more likely
to recall infections than healthy controls) has probably not played
an important role, as the associations we observed are inverse.
However, confounding may still have resulted from unmeasured
socioeconomic, genetic, and other lifestyle factors that differentiate
women who had infection from those who did not. Bladder
infection may be a marker of a greater susceptibility to all kinds of
infections and subsequently a greater likelihood of being
prescribed antibiotics. Lastly, bladder cancer patients with a
history of infection may be more likely to die, be too ill to be
interviewed, or decline participation in our study, thus leading to
potential selection bias, which could have explained some of our
observed associations.
Our results suggest that a history of bladder infection is
associated with a reduced risk of bladder cancer. Cytotoxicity
against bladder cancer cells from antibiotics commonly used to
treat bladder infections is proposed as a possible mechanism to
explain this association.
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